Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The distinctive nature of HER2-positive breast cancers.

× No keyword cloud information.

135 in total

1. The role of pharmacogenetics and pharmacogenomics in improving translational medicine.

Authors: Willard H Dere; Tamas S Suto
Journal: Clin Cases Miner Bone Metab Date: 2009-01

2. Single-Cell Intravital Microscopy of Trastuzumab Quantifies Heterogeneous in vivo Kinetics.

Authors: Ran Li; Adel Attari; Mark Prytyskach; Michelle A Garlin; Ralph Weissleder; Miles A Miller
Journal: Cytometry A Date: 2019-08-19 Impact factor: 4.355

3. SOX2 oncogenes amplified and operate to activate AKT signaling in gastric cancer and predict immunotherapy responsiveness.

Authors: Yajun Tian; Xin Jia; Shengxiang Wang; Yongsheng Li; Peng Zhao; Da Cai; Zequan Zhou; Junmin Wang; Yi Luo; Maosheng Dong
Journal: J Cancer Res Clin Oncol Date: 2014-04-22 Impact factor: 4.553

4. HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas.

Authors: Klaus Aumayr; Tobias Klatte; Barbara Neudert; Peter Birner; Shahrokh Shariat; Manuela Schmidinger; Martin Susani; Andrea Haitel
Journal: Pathol Oncol Res Date: 2017-07-28 Impact factor: 3.201

Review 5. Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.

Authors: Balazs I Bodai; Phillip Tuso
Journal: Perm J Date: 2015

6. Tracking and evaluating molecular tumor markers with cancer registry data: HER2 and breast cancer.

Authors: William F Anderson; Philip S Rosenberg; Hormuzd A Katki
Journal: J Natl Cancer Inst Date: 2014-04-28 Impact factor: 13.506

Review 7. Advanced development of ErbB family-targeted therapies in osteosarcoma treatment.

Authors: Wei Wang; Hua-Fu Zhao; Teng-Fei Yao; Hao Gong
Journal: Invest New Drugs Date: 2018-10-24 Impact factor: 3.850

8. Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer.

Authors: Masakazu Toi; Jeff Sperinde; Weidong Huang; Shigehira Saji; John Winslow; Xueguang Jin; Yuping Tan; Shinji Ohno; Seigo Nakamura; Hiroji Iwata; Norikazu Masuda; Kenjiro Aogi; Satoshi Morita; Christos Petropoulos; Michael Bates
Journal: BMC Cancer Date: 2010-02-23 Impact factor: 4.430

9. Augmented inhibition of angiogenesis by combination of HER2 antibody chA21 and trastuzumab in human ovarian carcinoma xenograft.

Authors: Anli Zhang; Guodong Shen; Ting Zhao; Guihong Zhang; Jing Liu; Lihua Song; Wei Wei; Ling Bing; Zhengsheng Wu; Qiang Wu
Journal: J Ovarian Res Date: 2010-08-19 Impact factor: 4.234

10. Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance.

Authors: Dimitrios H Roukos
Journal: Ann Surg Oncol Date: 2009-10-20 Impact factor: 5.344